Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07327411
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
A Single-arm, Multi-center, Prospective Clinical Study of Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Sponsor: Second Affiliated Hospital of Soochow University
Conditions
Advanced Refractory Solid Tumors
Updated 1 time since 2026 Last updated: Dec 25, 2025 Started: Dec 27, 2025 Primary completion: Feb 10, 2027 Completion: Nov 10, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Advanced Refractory Solid Tumors, this trial is actively recruiting participants. The trial is conducted by Second Affiliated Hospital of Soochow University and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Second Affiliated Hospital of Soochow University
Data source: Second Affiliated Hospital of Soochow University
For direct contact, visit the study record on ClinicalTrials.gov .